RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
-14.25%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$5.67B
AUM Growth
+$5.67B
(-21%)
Cap. Flow
+$149M
Cap. Flow
% of AUM
2.62%
Top 10 Holdings %
Top 10 Hldgs %
45.45%
Holding
105
New
10
Increased
9
Reduced
7
Closed
8
Top Buys
| 1 |
BLU
BELLUS Health Inc.
BLU
|
$82.4M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$55.9M |
| 3 |
LIAN
LianBio American Depositary Shares
LIAN
|
$47.2M |
| 4 |
Relmada Therapeutics
RLMD
|
$45.1M |
| 5 |
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
|
$34.8M |
Top Sells
| 1 |
Atea Pharmaceuticals
AVIR
|
$190M |
| 2 |
TG Therapeutics
TGTX
|
$35.9M |
| 3 |
VERV
Verve Therapeutics
VERV
|
$21M |
| 4 |
CytomX Therapeutics
CTMX
|
$17.8M |
| 5 |
WHWK
Whitehawk Therapeutics, Inc. Common Stock
WHWK
|
$10.2M |
Sector Composition
| 1 | Healthcare | 98.88% |
| 2 | Financials | 0.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $1.02B | 17.95% | 7,567,900 +180,000 | +2% | +$24.2M |
|
2
Novavax
NVAX
$1.21B
| $300M | 5.29% | 2,097,794 | – | – |
|
3
iTeos Therapeutics
ITOS
| $206M | 3.63% | 4,417,259 | – | – |
|
4
Travere Therapeutics
TVTX
$1.56B
| $174M | 3.07% | 5,614,428 | – | – |
|
5
Janux Therapeutics
JANX
$1.37B
| $171M | 3.02% | 8,670,644 | – | – |
|
6
Cytek Biosciences
CTKB
$527M
| $157M | 2.76% | 9,607,028 | – | – |
|
|
IMGN
7
DELISTED
Immunogen Inc
IMGN
| $150M | 2.65% | 20,241,458 +1,824,000 | +10% | +$13.5M |
|
|
CLYM
8
Climb Bio, Inc. Common Stock
CLYM
$151M
| $138M | 2.43% | 13,150,849 | – | – |
|
|
ICVX
9
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $132M | 2.33% | 5,779,347 | – | – |
|
|
DICE
10
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $132M | 2.32% | 5,208,911 | – | – |
|
11
Vor Biopharma
VOR
$250M
| $129M | 2.28% | 11,120,973 | – | – |
|
|
FMTX
12
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $128M | 2.26% | 9,011,651 | – | – |
|
13
Tyra Biosciences
TYRA
$675M
| $102M | 1.8% | 7,236,454 | – | – |
|
14
Vaxcyte
PCVX
$4B
| $101M | 1.78% | 4,240,464 +343,599 | +9% | +$8.17M |
|
15
MacroGenics
MGNX
$112M
| $98M | 1.73% | 6,103,594 +160,000 | +3% | +$2.57M |
|
|
JBIO
16
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $97.4M | 1.72% | 8,263,982 | – | – |
|
17
Nkarta
NKTX
$151M
| $86M | 1.52% | 5,605,129 | – | – |
|
18
Day One Biopharmaceuticals
DAWN
$769M
| $83.7M | 1.48% | 4,965,588 | – | – |
|
19
Instil Bio
TIL
$182M
| $83.3M | 1.47% | 4,870,793 | – | – |
|
|
BLU
20
DELISTED
BELLUS Health Inc.
BLU
| $82.4M | 1.45% | +10,230,274 | New | +$82.4M |
|
21
Celldex Therapeutics
CLDX
$1.47B
| $69.7M | 1.23% | 1,804,795 +204,795 | +13% | +$7.91M |
|
22
Tenaya Therapeutics
TNYA
$184M
| $67.3M | 1.19% | 3,551,508 | – | – |
|
23
GH Research
GHRS
$837M
| $66.3M | 1.17% | 2,843,757 -170,200 | -6% | -$3.97M |
|
24
Acumen Pharmaceuticals
ABOS
$82.4M
| $66.1M | 1.16% | 9,770,773 | – | – |
|
25
89bio
ETNB
$1.34B
| $64.9M | 1.14% | 4,965,769 | – | – |
|